Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Supply Chain Pharmaceuticals topic
No spam. Unsubscribe anytime.
Commenter says U.S. surrendered drug-making capacity to foreign suppliers, calls for policy reorientation
Summary
A meeting commenter warned that the United States has outsourced much of its pharmaceutical ingredient and generic drug production, leaving the country and others vulnerable and, the commenter said, requiring a reorientation of domestic industrial policy.
A commenter at the meeting said the United States has relinquished much of its pharmaceutical production and active pharmaceutical ingredient supply to other countries and urged a reorientation of domestic industrial and foreign policy to restore capacity.
The commenter said, "It happened because we literally gave it away. Because we made the decision, we made the policy decision that it was okay." The speaker added that "we were okay with 80 something percent of the active ingredients and most of our generic pharmaceuticals coming from another country."
The commenter framed the shift as a broader geopolitics problem, saying the global supply crunch shows how industrial capacity affects national security and economic resilience. "Now we are in a crunch," the commenter said, and added that the situation has led geopolitics to adjust. The speaker said restoring domestic capability will be "one of the great challenges of the new century" and described it as a priority "for the administration under President Trump," saying the United States must be able to "feed your people and ... make the things that your economy needs in order to function and ultimately to defend yourself."
Remarks in the transcript were discussion only; no motion, vote or formal action on industrial policy or pharmaceutical supply was recorded in this meeting.
No formal next steps or staff directions were announced in the portion of the transcript provided.
